Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy

Table 1 Patient characteristics

Number of patients	30
Sex
Male	21
Female	9
Age
−59	11
60–69	9
70−	10
Average	62.8
Site of colorectal cancer
Cecum	4
Ascending colon	3
Transverse colon	2
Descending colon	1
Sigmoid colon	7
Rectum	13
Rate of hospitalization	23 %
Overall treatment period (average)	13.5 months
Treatment lines
First-line	30
Second-line	20
Third-line	8
Regimens
Oxaliplatin-based regimens	13
FOLFOX	12
XELOX	1
Irinotecan-based regimens	31
IRIS	27
FOLFIRI	4
Regimens including molecular targeted agents	11
FOLFOX + Bev	6
FOLFIRI + Bev or Cet	4
XELOX + Bev	1
Others	3

Overall treatment period = from the beginning of treatment to the end of the final line of chemotherapy (All of the patients had died or were in terminal care phase as of the study endpoint)
The numbers of each regimen were counted from among all courses of treatment in all patients
FOLFOX oxaliplatin plus 5-fluorouracil and leucovorin; FOLFIRI irinotecan plus 5-fluorouracil and leucovorin; XELOX oxaliplatin plus capecitabine; IRIS irinotecan plus S-1 (tegafur, gimeracil and oteracil combination); Bev bevacizumab; Cet cetuximab; Others 2 Bev and 1 Cet

ISSN: 1472-6963